Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34


Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity.

Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH, Hudson TE, Vu UT, Francica BJ, Banda T, Katibah GE, Kanne DB, Leong JJ, Metchette K, Bruml JR, Ndubaku CO, McKenna JM, Feng Y, Zheng L, Bender SL, Cho CY, Leong ML, van Elsas A, Dubensky TW Jr, McWhirter SM.

Cell Rep. 2018 Dec 11;25(11):3074-3085.e5. doi: 10.1016/j.celrep.2018.11.047.


APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.

Tai YT, Lin L, Xing L, Cho SF, Yu T, Acharya C, Wen K, Hsieh PA, Dulos J, van Elsas A, Munshi N, Richardson P, Anderson KC.

Leukemia. 2019 Feb;33(2):426-438. doi: 10.1038/s41375-018-0242-6. Epub 2018 Aug 22.


Effects of a human recombinant alkaline phosphatase on renal hemodynamics, oxygenation and inflammation in two models of acute kidney injury.

Peters E, Ergin B, Kandil A, Gurel-Gurevin E, van Elsas A, Masereeuw R, Pickkers P, Ince C.

Toxicol Appl Pharmacol. 2016 Dec 15;313:88-96. doi: 10.1016/j.taap.2016.10.015. Epub 2016 Oct 17.


Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.

Houot R, Gaulard P, Schreiber R, Mellman I, Lambotte O, Coulie PG, Fest T, Korman A, Levy R, Shipp M, Tarte K, Kohrt H, Marabelle A, Ansell S, Watier H, van Elsas A, Balakumaran A, Arce Vargas F, Quezada SA, Salles G, Olive D.

Oncoimmunology. 2016 May 19;5(7):e1186323. doi: 10.1080/2162402X.2016.1186323. eCollection 2016 Jul.


Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers.

Peters E, Heuberger JAAC, Tiessen R, van Elsas A, Masereeuw R, Arend J, Stevens J, Pickkers P.

Clin Pharmacokinet. 2016 Oct;55(10):1227-1237. doi: 10.1007/s40262-016-0399-y.


APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

Tai YT, Acharya C, An G, Moschetta M, Zhong MY, Feng X, Cea M, Cagnetta A, Wen K, van Eenennaam H, van Elsas A, Qiu L, Richardson P, Munshi N, Anderson KC.

Blood. 2016 Jun 23;127(25):3225-36. doi: 10.1182/blood-2016-01-691162. Epub 2016 Apr 28.


Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!

van Elsas A, van Eenennaam H, Haanen JB.

Clin Cancer Res. 2015 Oct 1;21(19):4251-3. doi: 10.1158/1078-0432.CCR-15-1126. Epub 2015 Jul 13.


Improvement of the skeletal and dental hypophosphatasia phenotype in Alpl-/- mice by administration of soluble (non-targeted) chimeric alkaline phosphatase.

Gasque KC, Foster BL, Kuss P, Yadav MC, Liu J, Kiffer-Moreira T, van Elsas A, Hatch N, Somerman MJ, Millán JL.

Bone. 2015 Mar;72:137-47. doi: 10.1016/j.bone.2014.11.017. Epub 2014 Nov 26.


Catalytic signature of a heat-stable, chimeric human alkaline phosphatase with therapeutic potential.

Kiffer-Moreira T, Sheen CR, Gasque KC, Bolean M, Ciancaglini P, van Elsas A, Hoylaerts MF, Millán JL.

PLoS One. 2014 Feb 24;9(2):e89374. doi: 10.1371/journal.pone.0089374. eCollection 2014.


Alkaline phosphatase as a treatment of sepsis-associated acute kidney injury.

Peters E, van Elsas A, Heemskerk S, Jonk L, van der Hoeven J, Arend J, Masereeuw R, Pickkers P.

J Pharmacol Exp Ther. 2013 Jan;344(1):2-7. doi: 10.1124/jpet.112.198226. Epub 2012 Nov 6. Review.


CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction.

Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van Houdt M, Otten MA, Finetti P, Van Egmond M, Matozaki T, Kraal G, Birnbaum D, van Elsas A, Kuijpers TW, Bertucci F, van den Berg TK.

Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18342-7. doi: 10.1073/pnas.1106550108. Epub 2011 Oct 31.


Cannabinoid Receptor 2 Deficiency in Haematopoietic cells Aggravates Early Atherosclerosis in LDL Receptor Deficient Mice.

Delsing DJ, Leijten FP, Arts K, van Eenennaam H, Garritsen A, Gijbels MJ, de Winther MP, van Elsas A.

Open Cardiovasc Med J. 2011;5:15-21. doi: 10.2174/1874192401105010015. Epub 2011 Feb 15.


Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor.

Frijters R, Fleuren W, Toonen EJ, Tuckermann JP, Reichardt HM, van der Maaden H, van Elsas A, van Lierop MJ, Dokter W, de Vlieg J, Alkema W.

BMC Genomics. 2010 Jun 5;11:359. doi: 10.1186/1471-2164-11-359.


C5a-stimulated recruitment of beta-arrestin2 to the nonsignaling 7-transmembrane decoy receptor C5L2.

Van Lith LH, Oosterom J, Van Elsas A, Zaman GJ.

J Biomol Screen. 2009 Oct;14(9):1067-75. doi: 10.1177/1087057109341407. Epub 2009 Jul 29.


Systems biology for battling rheumatoid arthritis: application of the Entelos PhysioLab platform.

Rullmann JA, Struemper H, Defranoux NA, Ramanujan S, Meeuwisse CM, van Elsas A.

Syst Biol (Stevenage). 2005 Dec;152(4):256-62.


Target validation in silico: does the virtual patient cure the pharma pipeline?

Alkema W, Rullmann T, van Elsas A.

Expert Opin Ther Targets. 2006 Oct;10(5):635-8.


Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.

Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ.

J Exp Med. 2001 Sep 17;194(6):823-32.


Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.

van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP.

J Exp Med. 2001 Aug 20;194(4):481-9.


Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation.

Sullivan TJ, Letterio JJ, van Elsas A, Mamura M, van Amelsfort J, Sharpe S, Metzler B, Chambers CA, Allison JP.

Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2587-92. Epub 2001 Feb 20.


Costimulatory wars: the tumor menace.

Hurwitz AA, Kwon ED, van Elsas A.

Curr Opin Immunol. 2000 Oct;12(5):589-96. Review.


Influence of increased c-Myc expression on the growth characteristics of human melanoma.

Schlagbauer-Wadl H, Griffioen M, van Elsas A, Schrier PI, Pustelnik T, Eichler HG, Wolff K, Pehamberger H, Jansen B.

J Invest Dermatol. 1999 Mar;112(3):332-6.


p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis.

Zerp SF, van Elsas A, Peltenburg LT, Schrier PI.

Br J Cancer. 1999 Feb;79(5-6):921-6.


bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice.

Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Müller M, Wolff K, Eichler HG, Pehamberger H.

Nat Med. 1998 Feb;4(2):232-4.


Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological characterization of a melanoma vaccine.

van Elsas A, Aarnoudse C, van der Minne CE, van der Spek CW, Brouwenstijn N, Osanto S, Schrier PI.

J Immunother. 1997 Sep;20(5):343-53.


UV-induced N-ras mutations are T-cell targets in human melanoma.

van Elsas A, Scheibenbogen C, van der Minne C, Zerp SF, Keilholz U, Schrier PI.

Melanoma Res. 1997 Aug;7 Suppl 2:S107-13. Review.


Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis.

Jansen B, Schlagbauer-Wadl H, Eichler HG, Wolff K, van Elsas A, Schrier PI, Pehamberger H.

Cancer Res. 1997 Feb 1;57(3):362-5.


N-ras oncogene expression changes the growth characteristics of human melanoma in two independent SCID-hu mouse models.

Jansen B, Inoue SA, Wadl H, Eichler HG, Wolff K, Van Elsas A, Schrier PI, Pehamberger H.

Int J Cancer. 1996 Sep 17;67(6):821-5.


Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma.

van Elsas A, Zerp SF, van der Flier S, Krüse KM, Aarnoudse C, Hayward NK, Ruiter DJ, Schrier PI.

Am J Pathol. 1996 Sep;149(3):883-93.


Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.

van Elsas A, van der Burg SH, van der Minne CE, Borghi M, Mourer JS, Melief CJ, Schrier PI.

Eur J Immunol. 1996 Aug;26(8):1683-9.


Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201.

Van Elsas A, Nijman HW, Van der Minne CE, Mourer JS, Kast WM, Melief CJ, Schrier PI.

Int J Cancer. 1995 May 4;61(3):389-96.


CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells.

Visseren MJ, van Elsas A, van der Voort EI, Ressing ME, Kast WM, Schrier PI, Melief CJ.

J Immunol. 1995 Apr 15;154(8):3991-8.


Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction/single-stranded conformation polymorphism analysis.

van Elsas A, Zerp S, van der Flier S, Krüse-Wolters M, Vacca A, Ruiter DJ, Schrier P.

Recent Results Cancer Res. 1995;139:57-67.


ras oncogene activation does not induce sensitivity to natural killer cell-mediated lysis in human melanoma.

van Elsas A, van Deursen E, Wielders R, van den Berg-Bakker CA, Schrier PI.

J Invest Dermatol. 1994 Nov;103(5 Suppl):117S-121S.


Supplemental Content

Loading ...
Support Center